Real-world experience with pembrolizumab in patients with advanced melanoma: A large retrospective observational study

Pembrolizumab has been approved in the United States for treating advanced melanoma for >4 years. We examined real-world pembrolizumab use and associated outcomes in US oncology clinical practices, including patients who would not be eligible for clinical trials. Flatiron Health longitudinal data...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Frank Xiaoqing, Ou, Wanmei, Diede, Scott J., Whitman, Eric D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709121/
https://www.ncbi.nlm.nih.gov/pubmed/31348273
http://dx.doi.org/10.1097/MD.0000000000016542

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709121/
https://www.ncbi.nlm.nih.gov/pubmed/31348273
http://dx.doi.org/10.1097/MD.0000000000016542

Ejemplares similares